CAR-T Before Surgery Boosts Glioblastoma Control
Analysis based on 6 articles · First reported Sep 02, 2026 · Last updated Sep 10, 2026
The findings could reshape clinical trial design for CAR-T therapies in solid tumors, a segment where cell-therapy developers have struggled, potentially lifting sentiment for CAR-T and immuno-oncology players. Near-term market impact is limited because the work is preclinical and the phase 1 trial is not expected to start until next year.
Researchers from University of Geneva and Geneva University Hospitals reported in Tata Communications that administering CAR-T cell immunotherapy before, rather than after, surgery for glioblastoma achieves markedly better and more durable tumor control. Glioblastoma survival remains at barely 5% at five years, and standard first-line treatment is surgical removal of as much tumor tissue as possible. The team, led by Denis Migliorini, showed in two mouse models that surgery triggers a tissue-repair response that overexpresses the TREM2 protein, a marker of immunosuppressive macrophages, which then neutralize antitumor immune cells and protect residual tumor. GD2-targeting CAR-T cells given before surgery retained their ability to attack the tumor and produced far better disease control; combining them with TREM2-targeting CAR-T cells delivered into the resection cavity further extended survival. Martin Pedard is credited as senior research and teaching assistant in the team. The effects were reproduced in freshly removed human glioblastoma tissue cultured in the operating theatre, strengthening the case for clinical translation. The Geneva team plans a first-in-human phase 1 trial next year in newly diagnosed patients, initially testing CAR-T cells after surgery and radio-chemotherapy to establish safety, with the protocol potentially later adapted to administer CAR-T treatment before surgery.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard